| pubmed-article:21606259 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21606259 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:21606259 | lifeskim:mentions | umls-concept:C0138741 | lld:lifeskim |
| pubmed-article:21606259 | lifeskim:mentions | umls-concept:C1511790 | lld:lifeskim |
| pubmed-article:21606259 | lifeskim:mentions | umls-concept:C0456603 | lld:lifeskim |
| pubmed-article:21606259 | lifeskim:mentions | umls-concept:C0024485 | lld:lifeskim |
| pubmed-article:21606259 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:21606259 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21606259 | pubmed:dateCreated | 2011-5-24 | lld:pubmed |
| pubmed-article:21606259 | pubmed:abstractText | The purpose of the study was to assess the predictive value for prostate cancer of MRI using morphologic (T2-weighted imaging [T2WI]) and functional (MR spectroscopy [MRS], diffusion-weighted imaging [DWI], and dynamic contrast-enhanced [DCE] MRI) sequences and the free-to-total prostate-specific antigen (PSA) ratio, alone and combined. | lld:pubmed |
| pubmed-article:21606259 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21606259 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21606259 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21606259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21606259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21606259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21606259 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21606259 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21606259 | pubmed:issn | 1546-3141 | lld:pubmed |
| pubmed-article:21606259 | pubmed:author | pubmed-author:AlbanellJoanJ | lld:pubmed |
| pubmed-article:21606259 | pubmed:author | pubmed-author:FerrerJoanaJ | lld:pubmed |
| pubmed-article:21606259 | pubmed:author | pubmed-author:VilanovaJoan... | lld:pubmed |
| pubmed-article:21606259 | pubmed:author | pubmed-author:BarcelóJoaqui... | lld:pubmed |
| pubmed-article:21606259 | pubmed:author | pubmed-author:CometJosepJ | lld:pubmed |
| pubmed-article:21606259 | pubmed:author | pubmed-author:Barceló-Vidal... | lld:pubmed |
| pubmed-article:21606259 | pubmed:author | pubmed-author:BoadaMariaM | lld:pubmed |
| pubmed-article:21606259 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21606259 | pubmed:volume | 196 | lld:pubmed |
| pubmed-article:21606259 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21606259 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21606259 | pubmed:pagination | W715-22 | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:meshHeading | pubmed-meshheading:21606259... | lld:pubmed |
| pubmed-article:21606259 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21606259 | pubmed:articleTitle | Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. | lld:pubmed |
| pubmed-article:21606259 | pubmed:affiliation | Department of MRI, Clínica Girona, Lorenzana 36, Girona 17002, Spain. kvilanova@comg.cat | lld:pubmed |
| pubmed-article:21606259 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21606259 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
